Generic Name and Formulations:
Varicella zoster vaccine recombinant, adjuvanted; susp for IM inj after reconstitution (contains 50mcg of recombinant glycoprotein E antigen, 50mcg of monophosphoryl lipid A, and 50mcg of QS-21); per 0.5mL; preservative-free.
Indications for SHINGRIX:
Prevention of herpes zoster (shingles) in adults ≥50yrs of age.
Limitations Of use:
Not for preventing primary varicella infection (chickenpox).
<50yrs: not recommended. Give by IM inj in deltoid region of upper arm. ≥50yrs: one 0.5mL dose at Month 0 followed by second dose anytime between 2–6 months later. Administer immediately upon reconstitution or store refrigerated and use within 6hrs.
<18yrs: not established.
Allergies to any previous Shingrix vaccination.
Review immunization history prior to administration. Have appropriate medical treatment and supervision available to manage allergic reactions. Pregnancy. Nursing mothers.
Immunosuppressants may reduce efficacy of Shingrix. Concomitant inactivated influenza vaccines: see full labeling.
Local reactions (eg, pain, redness, swelling), myalgia, fatigue, headache, shivering, fever, GI symptoms.
To report adverse events, contact VAERS at (800) 822-7967.
Single-dose vials—1, 10 (antigen + adjuvant components)
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- OnabotulinumtoxinA May Be Effective for Chronic Migraine With Medication Overuse
- FDA Outlines Plan for Increasing Nonprescription Drug Availability
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Hypoesthesia for Touch and Joint Position Linked to Chronic Pain in MS
- New Laws Are Needed to Protect Health Data Shared Online